



# Press Release

**FOR IMMEDIATE RELEASE**

## **CRITICAL OUTCOME TECHNOLOGIES INC. ANNOUNCES THE ISSUANCE OF STOCK OPTIONS**

**London, Ontario (February 16, 2010): Critical Outcome Technologies Inc. (COTI) (TSX Venture: COT)** announced today that 246,808 stock options were approved for grant to eight employees under the Company's Stock Option Plan on February 12, 2010. The options vested immediately, have a life of five years and are exercisable at a price of \$0.47 per share. The exercise price represents the closing price of the Company's common shares on February 11, 2010, the last trade reported on the TSX Venture Exchange prior to the meeting date.

### **About Critical Outcome Technologies Inc. (COTI)**

COTI is formed around a unique computational platform technology called CHEMSAS®, which allows for the accelerated identification, profiling and optimization of targeted small molecules potentially effective in the treatment of human diseases for which current therapy is either lacking or ineffective. Currently, six targeted libraries of lead compounds are under active development; small cell lung cancer, multiple sclerosis, HIV integrase inhibitors, adult acute leukemia, colorectal cancer and Alzheimer's disease.

For more information, please visit our website [www.criticaloutcome.com](http://www.criticaloutcome.com) or contact us at 519-858-5157:

Contacts:

Michael Cloutier, CEO  
Dr. Wayne Danter, President & CSO  
Gene Kelly, Chief Financial Officer

[mcloutier@criticaloutcome.com](mailto:mcloutier@criticaloutcome.com)  
[wdanter@criticaloutcome.com](mailto:wdanter@criticaloutcome.com)  
[gkelly@criticaloutcome.com](mailto:gkelly@criticaloutcome.com)

*Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.*